Myeloproliferative neoplasms (MPNs) are a class of hematological cancers characterized by the excessive production of a particular blood cell. MPNs is an umbrella term covering disorders such as myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Pathological features are a key aspect of MPN diagnostics, hence improvements in digitally visualizing pathology and the use of machine learning for tracking patients will aid the field. Multiple clinical trials are underway for different therapeutic agents, including calreticulin-directed vaccines and antibodies for ET and MF. There are three approved JAK inhibitors for MF: ruxolitinib, fedratinib and pacritinib. An evolving question is whether combinations of JAK inhibitors will further the benefits observed in monotherapy, and if combinations will go as far as achieving disease modification.

In this exclusive podcast, leading experts Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, hold a fascinating discussion on current developments in the management and treatment of MPNs.

The post Key updates in the treatment and management of MPNs appeared first on VJHemOnc.